A 2026 review pooled eight randomized trials with 664 participants receiving antipsychotics. The mean difference in weight was −6.74 kg compared with control (95% confidence interval, −10.05 to −3.43 kg). Nausea, vomiting, and constipation were more common with GLP-1 treatment. If you are reviewing GLP-1 side effects with your prescribers, mention any symptoms you already have so they can plan how to monitor changes.[1]
What trials measured about psychiatric symptoms
HISTORI randomized 154 adults with schizophrenia, prediabetes, and overweight or obesity who were on stable second-generation antipsychotic treatment. At 30 weeks, semaglutide reduced weight by 9.21 kg more than placebo. Researchers found no statistically significant group difference in the PANSS-6 schizophrenia symptom score or mental quality of life. A few people receiving semaglutide had more frequent hospitalizations. The study found no statistically significant difference in serious adverse events overall.[2]
COaST randomized 31 adults with schizophrenia and obesity who were taking clozapine. At 36 weeks, the trial found no group differences in schizophrenia symptom scores or in clozapine and norclozapine concentrations. The two trials provide information about the groups they studied. Their size and follow-up leave uncertainty about uncommon events and longer-term outcomes.[3]
Medication review and follow-up
The guide to lab monitoring during GLP-1 treatment explains common tests. Both the Wegovy and Zepbound labels warn that delayed stomach emptying can affect how oral medicines are absorbed. The labels call for attention to medicines that need close monitoring.[4][5]
Ask the clinicians managing both treatments what they want to track for your particular medicines, and consult them before changing either prescription.